Loading...
•
Dec 31, 2023
Vaxcyte Q4 2023 Earnings Report
Vaxcyte reported fourth quarter and full year 2023 financial results and provided a business update.
Key Takeaways
Vaxcyte reported a net loss of $180.8 million for the fourth quarter of 2023. The company's cash, cash equivalents and investments were $1,242.9 million as of December 31, 2023, excluding net proceeds of $816.5 million from a recent public offering. The company also completed enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of IPD in Adults Aged 50 and Older.
Completed Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of IPD in Adults Aged 50 and Older; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024
Completed Successful VAX-24 Phase 2 Adult Program and End-of-Phase 2 Meeting; VAX-24 is Phase 3-Ready in Adults
Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program
Completed Two Successful Follow-On Financings Totaling Approximately $1.4 Billion in Gross Proceeds, Further Strengthening Vaxcyte’s Balance Sheet
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...